<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763373</url>
  </required_header>
  <id_info>
    <org_study_id>Antibiotic Switch</org_study_id>
    <nct_id>NCT00763373</nct_id>
  </id_info>
  <brief_title>Unnecessary IV Antibiotic Days Using General Criteria for Antibiotic Switch</brief_title>
  <official_title>Unnecessary IV Antibiotic Days Using General Criteria for Antibiotic Switch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorlandet Hospital HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observation of the use of intravenous antibiotics in medical clinic of Sorlandet Hospital,&#xD;
      Norway. Suggestions of criteria for the switch from intravenous to oral administration of&#xD;
      antibiotics. Implementation of the criteria and new registration of the use of intravenous&#xD;
      antibiotics. Comparison of the amount of the iv-administration before and after the&#xD;
      intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a comparison of the use of intravenous antibiotics before and after the&#xD;
      implementation of switch criteria. Switch is defined as a change in administration route from&#xD;
      intravenous to oral.&#xD;
&#xD;
      Patients administered to medical department at Sorlandet hospital in Kristiansand and Arendal&#xD;
      are included if they are receiving intravenous antibiotics. Pediatric department is not&#xD;
      included. Patients that are already hospitalized and given intravenous antibiotics are also&#xD;
      included.&#xD;
&#xD;
      Patients that are excluded are those with CNS-infection, endocarditis, bone/joint infection,&#xD;
      deep undrainable abscesses and those with foreign body infection.&#xD;
&#xD;
      Switch criteria are made from a thorough investigation on earlier switch studies. We have&#xD;
      collected several studies on this topic, but none from the nordic countries.&#xD;
&#xD;
      The intervention contributes the following: The implementation of a registration form where&#xD;
      doctors are prone to answer six questions when they evaluate antibiotic administration form.&#xD;
&#xD;
        1. Are there special iv-indications? (CNS-infection, endocarditis, bone/joint infection,&#xD;
           deep undrainable abscesses or foreign body infection)&#xD;
&#xD;
        2. Is the oral route compromized? (unconscious, nausea, vomiting, diarrhoea, dysphagia,&#xD;
           lack of cooperativeness)&#xD;
&#xD;
        3. Is the patients suffering from immunosuppression? (leukopenia, cytotoxic treatment,&#xD;
           transplantation, steroids &gt;10mg, TNF-alfa inhibitor treatment, unregulated diabetes&#xD;
           mellitus (HbA1C &gt;10), uremia (serum-creatinine &gt; 300), HIV, AIDS, lymphoma, multiple&#xD;
           myelomas, cystic fibrosis, asplenic)&#xD;
&#xD;
        4. Is the systemic inflammatory response syndrome present?&#xD;
&#xD;
        5. Is the preferred antibiotics only available in intravenous form?&#xD;
&#xD;
        6. Are there any other special reasons for intravenous antibiotics?&#xD;
&#xD;
      If the doctor can answer NO to all these questions, then the patient is a candidate for&#xD;
      antibiotic switch from day three after hospitalization. This evaluation form follows the&#xD;
      other medical registration forms from day to day.&#xD;
&#xD;
      The intervention also includes&#xD;
&#xD;
        -  A lecture by the study group to all our medical doctors.&#xD;
&#xD;
        -  Information by e-mail to all our medical doctors&#xD;
&#xD;
        -  Information by letters to all our medical doctors and chief nurses&#xD;
&#xD;
      Registration of parameters used for evaluating antibiotic switch is done three times a week&#xD;
      by the study group. We register date and patient information, if other medication is taken&#xD;
      orally, heart rate, respiratory rate, temperature, biochemical parameters (CRP and&#xD;
      leukocytes), diagnosis and antibiotic choice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Reduction in the amount of intravenous antibiotic days</measure>
    <time_frame>During stay</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital stay duration, re-admittance, re-prescription of intravenous antibiotic therapy</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">187</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Observation group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Intervention group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Implementation of antibiotic switch guidelines</intervention_name>
    <description>Implementation of antibiotic switch guidelines</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Antibiotic switch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alle patients with suspected infection and who is gives intravenous antibiotics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CNS-infection&#xD;
&#xD;
          -  Endocarditis&#xD;
&#xD;
          -  Bone/joint infection&#xD;
&#xD;
          -  Undrained abscess&#xD;
&#xD;
          -  Foreign body infection&#xD;
&#xD;
          -  Compromized oral route&#xD;
&#xD;
          -  Immunosuppression&#xD;
&#xD;
          -  Patients meeting the systemic inflammatory response syndrome criteria&#xD;
&#xD;
          -  No preferred oral antibiotic available&#xD;
&#xD;
          -  Other conditions requiring intravenous administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjoern Waagsboe, Ass dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical department Kristiansand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Sundoy, Chief Doc</last_name>
    <role>Study Director</role>
    <affiliation>Medical dep kristiansand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Else Quist Paulsen, ass doc</last_name>
    <role>Study Director</role>
    <affiliation>Med dep Arendal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sorlandet Sykehus Arendal</name>
      <address>
        <city>Arendal</city>
        <state>Aust-Agder</state>
        <zip>4500</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SÃ¸rlandet Sykehus Kristiansand</name>
      <address>
        <city>Kristiansand</city>
        <state>Vest Agder</state>
        <zip>4604</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>August 16, 2007</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <last_update_submitted>September 29, 2008</last_update_submitted>
  <last_update_submitted_qc>September 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Bjoern Waagsboe</name_title>
    <organization>Sorlandet Sykehus HF</organization>
  </responsible_party>
  <keyword>Lower respiratory infection</keyword>
  <keyword>Upper respiratory infection</keyword>
  <keyword>Urinary tract infection</keyword>
  <keyword>Soft tissue infection</keyword>
  <keyword>Hepatobiliary infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

